Related Experiment Video
Updated: May 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Dynamic APTT parameters: applications in thrombophilia
1Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation & King's College London School of Medicine, London, UK. benny.sorensen@kcl.ac.uk
Background:
Patients with a history of venous thrombosis occasionally have shortened APTTs when compared with those of healthy references, but the clinical applicability of a shortened APTT is limited.
Objectives:
The present study aimed to characterize dynamic APTT profiles in patients with previously documented venous thrombosis and hypothesized that the APTT-MaxVel was significantly elevated in patients with a history of venous thrombosis as compared with healthy controls.
Methods:
We performed a case control study, enrolling a total of 38 patients, 17 males and 21 females, with a verified recent venous thrombotic event, as well as 88 healthy controls. Fifty-three per cent of patients were found to have a biochemical risk factor. A standard APTT was recorded in platelet-poor plasma, and the digital clotting signal was processed using simple algorithms developed to derive dynamic coagulation parameters.
Results:
Patients had a significantly higher mean APTT-MaxVel (195.5 s(-1) ; SD = 57; 95% CI, 176.8-214.1) as compared with healthy controls (137.3 s(-1) ; SD = 21; 95% CI, 130.7-143.8). Patients also had significantly shorter mean APTTs (26.9 s; SD = 3.2; 95% CI, 25.9-28.0) than healthy controls (28.5 s; SD = 2.8; 95% CI, 27.9-29.0). While only one out of 38 patients (2.6%) had a standard APTT below the lower reference interval, 15 of the 38 patients (38.5%) had an APTT-MaxVel above the upper reference limit. Regression analysis revealed linear correlation between FVIII:C, the level of fibrinogen and APTT-MaxVel (R(2) = 0.89, P < 0.05).
Conclusions:
Simple signal processing of the APTT and the use of dynamic parameters represents a stronger predictive marker for hypercoagulation in patients with verified venous thrombosis than the standard APTT measurement.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis

